Pfizer (NYSE:PFE) Stock Price Up 1.5% – Still a Buy?

Pfizer Inc. (NYSE:PFE) shares were up 1.5% during mid-day trading on Wednesday . The stock traded as high as $25.92 and last traded at $25.90. Approximately 45,547,914 shares were traded during trading, a decline of 7% from the average daily volume of 48,881,133 shares. The stock had previously closed at $25.52.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst/media endorsement: The Motley Fool lists Pfizer as one of three “no‑brainer” dividend stocks to buy, highlighting income investors’ interest in PFE’s yield and shareholder return prospects. 3 No-Brainer Dividend Stocks to Buy Right Now — Including Pfizer
• Positive Sentiment: Strategic deal flow: Pfizer struck a licensing arrangement with Novavax around the Matrix‑M adjuvant to support vaccine development — a deal that can broaden Pfizer’s vaccine toolbox and pipeline optionality even if it includes payments to Novavax. Markets often view productive R&D partnerships as constructive for future growth. Novavax enters license agreement with Pfizer for vaccine development
• Neutral Sentiment: Management commentary: CEO Albert Bourla discussed drug pricing trends and AI in healthcare on ‘Money Movers’ — useful directional color on strategy but not an immediate earnings change. Investors will watch for policy specifics and margin impact. Pfizer CEO Albert Bourla: U.S. drug prices are coming down
• Neutral Sentiment: Industry outlook: Takeaways from the JPMorgan Healthcare Conference (coverage by CNBC) emphasize drug‑pricing pressure, patent cliffs and dealmaking across pharma — themes that shape long‑term investor expectations but are already baked into many valuations. Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
• Neutral Sentiment: Valuation check: Commentary assessing Pfizer’s valuation as investors reassess recent shareholder returns underscores that PFE is viewed as a value/dividend play by some, while others point to competitive and pricing risks. Pfizer (PFE) Valuation Check As Investors Reassess Recent Shareholder Returns
• Negative Sentiment: Asset reallocation: Pfizer is exiting its 11.7% stake in HIV specialist ViiV Healthcare as Shionogi increases its holding — a move that reduces Pfizer’s direct exposure to that JV’s upside and signals portfolio reshaping that may remove a future revenue stream. Japan’s Shionogi boosts ViiV stake to 21.7% as Pfizer exits
• Negative Sentiment: Competitive pressure: Analyst comparisons (Zacks) highlight Eli Lilly’s accelerating growth from GLP‑1 drugs as a competitive headwind across large-cap pharma; sustained outperformance by peers can weigh on Pfizer’s relative multiple. Which Pharma Stock Stands Taller Right Now: LLY or PFE?

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Bank of America cut their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $27.88.

Pfizer Stock Performance

The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm’s fifty day moving average price is $25.38 and its 200 day moving average price is $24.99. The firm has a market capitalization of $147.26 billion, a PE ratio of 15.06 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s payout ratio is currently 100.00%.

Hedge Funds Weigh In On Pfizer

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares in the last quarter. Park Avenue Securities LLC bought a new stake in Pfizer during the 2nd quarter worth about $3,807,000. Armstrong Advisory Group Inc. increased its position in Pfizer by 48.0% in the 2nd quarter. Armstrong Advisory Group Inc. now owns 8,920 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 2,895 shares in the last quarter. Finally, Golden State Equity Partners raised its stake in shares of Pfizer by 56.1% in the second quarter. Golden State Equity Partners now owns 28,797 shares of the biopharmaceutical company’s stock worth $698,000 after acquiring an additional 10,348 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.